Pricing & Access· August 8, 2026 · 14 min read
Novo Nordisk portfolio dossier (Q2 2026): Wegovy, CagriSema & obesity pipeline
By Ran Chen#Novo Nordisk#Semaglutide#Wegovy
Topic
Obesity
Obesity drug access, GLP-1 and multi-mechanism coverage, payer restrictions, step therapy, and the evolving formulary landscape for weight management.
Pricing & Access· June 24, 2026 · 25 min read
Eli Lilly Portfolio Dossier: Diabetes, Obesity, and Insulin Pricing
Pricing & Access· June 6, 2026 · 14 min read
Aetna GLP-1 coverage: PA criteria, formulary tiers, and 2026 plan rules
By Ran Chen#GLP-1#Aetna#Prior Authorization
Pricing & Access· June 6, 2026 · 12 min read
Ambetter GLP-1 coverage: Centene marketplace rules, PA criteria, and 2026 exclusions
Pricing & Access· June 6, 2026 · 13 min read
Anthem BCBS GLP-1 coverage: PA criteria, formulary tiers, and 2026 plan rules
By Ran Chen#GLP-1#Anthem#Blue Cross Blue Shield
Pricing & Access· June 6, 2026 · 11 min read
Blue Cross Blue Shield GLP-1 coverage policy and exclusions in 2026
Pricing & Access· June 6, 2026 · 11 min read
BCBSTX GLP-1 coverage: formulary rules, PA criteria, and 2026 updates for Texas members
Pricing & Access· June 6, 2026 · 12 min read
CareFirst BCBS GLP-1 coverage: PA criteria and Medicaid vs commercial
By Ran Chen#GLP-1#CareFirst#Blue Cross Blue Shield
Pricing & Access· June 6, 2026 · 10 min read
CHAMPVA GLP-1 coverage: covered drugs, exclusions, and 2025 policy changes
By Ran Chen#GLP-1#CHAMPVA#Prior Authorization
Pricing & Access· June 6, 2026 · 15 min read
Cigna GLP-1 coverage: PA criteria, Express Scripts formulary, 2026 rules
By Ran Chen#GLP-1#Cigna#Express Scripts